SubHero Banner

Immediate-release opioids – Safety update

September 28, 2017 – The FDA announced that a Risk Evaluation and Mitigation Strategy (REMS) is necessary for immediate-release (IR) opioid analgesics to ensure that the benefits of these drugs continue to outweigh the risks, and the IR opioid analgesics that are intended to be used in the outpatient setting will be subject to the same REMS requirements as the extended-release/long-acting (ER/LA) opioid analgesics.

Download PDF